Becton Dickinson and Co BDX reported Q1 FY22 revenues of $4.9 billion, down 6% Y/Y (-5.9% on a currency-neutral basis), better than the consensus of $4.76 billion.
- Excluding COVID-19 only diagnostic testing sales, base revenues increased 8.1% (8.3%) to $4.81 billion.
- COVID-19-only Diagnostic testing revenues declined from $866 million in Q4 FY20 to $185 million.
- Medical segment sales increased 6% Y/Y at $2.39 billion.
- Life Sciences segment sales declined 25% Y/Y at $1.48 billion, reflecting the decline in COVID-only testing revenues.
- Interventional segment revenues grew 3.7% Y/Y to $1.1 billion, led by surgery & peripheral intervention performance, reflecting a continued recovery in elective volumes.
- Operating income decreased 34% Y/Y to $815 million, and margin contracted from 23.3% to 16.3%.
- Adjusted EPS of $3.64, down from $4.55 a year ago, topping the consensus of $2.85.
- Guidance: BD expects FY22 sales of $19.55 billion - $19.75 billion, higher than prior guidance of $19.3 billion -$19.5 billion, versus the consensus of $19.43 billion.
- The company forecasts approximately $450 million in COVID-19-only diagnostic testing revenues, higher than roughly $200 million previously announced.
- The company anticipates FY22 adjusted EPS of $12.80 - $13.00, compared to $12.30 - $12.50 previously, and ahead of the consensus of $12.42.
- Price Action: BDX shares are up 4.60% at $268.54 on the last check Thursday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in